https://pubmed.ncbi.nlm.nih.gov/33973272/
Now Atl1102 reduces a unique type of inflammation in the body of DMD patients.Also reduces fibrosis (Mediated fibrosis) known in DMD:
We know this by our excellent data generated.
No Pharma even close to helping non ambulant patients.
Anp is in the Box seat with DMD. / limb girdle.
So people don’t listen to the negative noise
Remember
DMD is our primary objective and that trial start is not very far away .
We wait $$ ($10 billion market for DMD in 2030)
Ann: PIIb DMD trial approved in Bulgaria- UK, Australia advancing, page-11
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
